Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide

<table>(a) Flow cytometry results at diagnosis with gating scheme for CD34 versus HLA-DR. (b) Flow cytometry results at diagnosis with gating scheme CD13 versus CD34.</table>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide 

Figure 2 | Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide 